Holen Sie sich die Stockscreener-App
549.50
1.12%
-6.4076
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$555.91
Offen:
$556.31
24-Stunden-Volumen:
77,397
Relative Volume:
0.15
Marktkapitalisierung:
$23.32B
Einnahmen:
$3.17B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.28
EPS:
27.0947
Netto-Cashflow:
$1.01B
1W Leistung:
+0.88%
1M Leistung:
-0.03%
6M Leistung:
+9.35%
1J Leistung:
+86.66%
1-Tages-Spanne:
$546.99
$556.45
1-Wochen-Bereich:
$535.63
$558.59
52-Wochen-Spanne:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
549.38 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.78 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.66 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.05 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.77 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026 - Yahoo Finance
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 30 June By Investing.com - Investing.com Canada
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock - Investing.com
Big Pharma Has a Case of Merger Mania - The Motley Fool
United Therapeutics Corporation 8-K Filing Details: Stock Incentive Plan, Key Shareholder Info & SEC Compliance (June 2026) – Minichart - Minichart
FDA approves United Therapeutics’ LungFX lung perfusion device By Investing.com - Investing.com South Africa
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs - Benzinga
United Therapeutics (UTHR) Secures FDA Approval for LungFX - GuruFocus
United Therapeutics (UTHR) Receives FDA Approval for LungFX Devi - GuruFocus
FDA approves United Therapeutics’ LungFX lung perfusion device - Investing.com
FDA approves United Therapeutics' LungFX to assess donor lungs - Stock Titan
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 26 June By Investing.com - Investing.com Canada
United Therapeutics Corp Annual Shareholders Meeting Transcript - GuruFocus
Martine A. Rothblatt sells $5.2m United Therapeutics shares - Investing.com UK
Martine A. Rothblatt sells $5.2m United Therapeutics shares By Investing.com - Investing.com Australia
Form 4 United Therapeutics Corporation For: 25 June By Investing.com - Investing.com Nigeria
United Therapeutics chairperson & CEO sells $5.17m in stock - Investing.com UK
United Therapeutics chairperson & CEO sells $5.17m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 24 June By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares - Investing.com
United Therapeutics - Forbes
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock By Investing.com - Investing.com Australia
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock - Investing.com UK
Form 4 United Therapeutics Corporation For: 22 June By Investing.com - Investing.com Australia
United Therapeutics Corp (UTHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks - StockStory
United Therapeutics EVP Mahon sells $4.5m in company stock - Investing.com UK
United Therapeutics EVP Mahon sells $4.5m in company stock By Investing.com - Investing.com South Africa
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 02 '26 |
Sale |
554.61 |
9,500 |
5,268,781 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 02 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 02 '26 |
Sale |
552.56 |
8,300 |
4,586,275 |
45,172 |
0.40%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):